Company Allergy Therapeutics plc

Equities

AGY

GB00B02LCQ05

Biotechnology & Medical Research

Delayed London S.E. 05:13:15 2024-04-26 am EDT 5-day change 1st Jan Change
2.9 GBX +1.75% Intraday chart for Allergy Therapeutics plc +9.43% +16.00%

Business Summary

Allergy Therapeutics plc is a United Kingdom-based integrated specialty pharmaceutical company. The Company is focused on the treatment and diagnosis of allergic disorders, including aluminum-free immunotherapy vaccines that have the potential to cure disease. The Company sells proprietary and third-party products from its subsidiaries in nine European countries and via distribution agreements in an additional ten countries. Its pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA, Bee Venom SCIT, Wasp Venom SCIT, Ragweed MATA MPL, Trees MATA, Trees MATA MPL, Peanut SCIT and others. Its commercial portfolio of products includes Pollinex, Venomil and Acarovac. It operates in Austria, Germany, Italy, the Netherlands, Spain, Switzerland, and the United Kingdom.

Sales per Business

GBP in Million2022Weight2023Weight Delta
Pharmaceutical Products
100.0 %
73 100.0 % 60 100.0 % -18.11%

Sales per region

GBP in Million2022Weight2023Weight Delta
Germany
53.0 %
43 59.0 % 32 53.0 % -26.44%
Spain
16.0 %
9 12.0 % 10 16.0 % +9.18%
Austria
8.0 %
5 7.0 % 5 8.0 % -6.42%
Netherlands
7.0 %
4 6.0 % 4 7.0 % -4.47%
Switzerland
5.0 %
3 4.0 % 3 5.0 % +2.36%
Italy
5.0 %
4 5.0 % 3 5.0 % -18.11%
United Kingdom
3.0 %
1 2.0 % 2 3.0 % +22.83%
Czech and Slovak
2.0 %
2 3.0 % 1 2.0 % -45.41%
Other
1.0 %
1 2.0 % 1 1.0 % -59.06%

Managers

Managers TitleAgeSince
Chief Executive Officer 60 09-06-30
Director of Finance/CFO - 22-03-31
Chief Tech/Sci/R&D Officer - 03-12-31
Corporate Officer/Principal - 13-04-30
Human Resources Officer - -

Members of the board

Members of the board TitleAgeSince
Director/Board Member 67 17-06-05
Chairman 73 10-09-30
Director/Board Member - 22-12-05
Chief Executive Officer 60 09-06-30
Director/Board Member 45 22-12-05
Director/Board Member 56 21-10-26

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 4,766,439,938 323,443,304 ( 6.786 %) 0 6.786 %

Shareholders

NameEquities%Valuation
Skygem Acquisition Ltd.
65.00 %
3,098,231,533 65.00 % 117 M p
Southern Fox Investments Ltd.
27.43 %
1,307,377,398 27.43 % 50 M p
142,136,143 2.982 % 5 M p
JPMorgan Chase Bank, NA (Investment Management)
2.601 %
123,995,000 2.601 % 5 M p
GSK PLC
0.4612 %
21,982,110 0.4612 % 833 122 p
Spearling, Inc.
0.4441 %
21,167,000 0.4441 % 802 229 p
Hargreaves Lansdown Asset Management Ltd.
0.3358 %
16,004,000 0.3358 % 606 552 p
West Yorkshire Pension Fund
0.2911 %
13,877,000 0.2911 % 525 938 p
Panmure Gordon (UK) Ltd.
0.2145 %
10,223,000 0.2145 % 387 452 p
IG Markets Ltd.
0.1878 %
8,952,000 0.1878 % 339 281 p

Company contact information

Allergy Therapeutics Plc

Dominion Way

BN14 8SA, Worthing

+44 1903 844 700

http://www.allergytherapeutics.com
address Allergy Therapeutics plc(AGY)
  1. Stock Market
  2. Equities
  3. AGY Stock
  4. Company Allergy Therapeutics plc